Sequenom to Embark on Clinical Validation Study for Trisomy 21 Test in January

Results from an equivalency study using the HiSeq 2000 "met pre-specified requirements that now allow us to proceed confidently with the validation study," said Sequenom CEO Harry Hixson.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.